|drug557||CELLECTRA® 2000 Wiki||0.50|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a pandemic disease with worldwide spreading. Limited data are existed regarding SARS-CoV-2 positive carriers among asymptomatic medical employees in non-profile infectious clinic, e.g. cardiovascular clinic, routinely working in the pandemic region with two million inhabitants. The aim is to test the percentage and increase of the SARS-CoV-2 positive carriers among asymptomatic medical employees in high-volume cardiovascular center in routine clinical practice.
Description: Percentage of SARS-CoV-2 positive tests and increase of SARS-CoV-2 positive test between 1 st , 2 nd and 3 rd time frame testingMeasure: SARS-CoV-2 positive test Time: 8 weeks
Description: Percentage of transformation from asymptomatic SARS-CoV-2 positive carriers to symptomatic formMeasure: Transformation Time: 8 weeks
Description: Predictors of the asymptomatic SARS-CoV-2 positive carriersMeasure: Predictors (asymptomatic) Time: 8 weeks
Description: Predictors of symptomatic form transformationMeasure: Predictors (symptomatic) Time: 8 weeks
Description: Percentage of employees from different departments with SARS-CoV-2 positive carriersMeasure: Percentage from different departments Time: 8 weeks
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports